Eprosartan
Authors:
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 55 (5) , 713-718
Abstract
▴ Eprosartan is a nonpeptide angiotensin II receptor antagonist which has a high affinity for the AT1 receptor subtype. ▴ When administered at dosages of 400 to 800 mg/day (once or twice daily) for 13 weeks to patients with mild to moderate essential hypertension, eprosartan significantly reduced blood pressure compared with placebo. ▴ Eprosartan was at least as effective as enalapril 10 to 40 mg/day in a dose-titration study in patients with severe hypertension. ▴ Eprosartan is generally well tolerated; clinical trials have shown the drug to have a tolerability profile similar to that of placebo. As with other angiotensin II receptor antagonists, it does not cause cough. ▴ Eprosartan is not metabolised by the cytochrome P450 system and therefore has a low potential for drug interactions.Keywords
This publication has 12 references indexed in Scilit:
- Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of foodBiopharmaceutics & Drug Disposition, 1998
- Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.The Journal of Clinical Pharmacology, 1998
- Effect of Hepatic Disease on the Pharmacokinetics and Plasma Protein Binding of EprosartanPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
- A Dose Proportionality Study of Eprosartan in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1998
- Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*Clinical Pharmacology & Therapeutics, 1997
- Renal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy MenHypertension, 1997
- Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers1997
- Eprosartan, an Angiotensin II Receptor Antagonist, Does Not Affect the Pharmacodynamics of Glyburide in Patients with Type II Diabetes MellitusThe Journal of Clinical Pharmacology, 1997
- Inhibition of Sympathetic Outflow by the Angiotensin II Receptor Antagonist, Eprosartan, but Not by Losartan, Valsartan or Irbesartan: Relationship to Differences in Prejunctional Angiotensin II Receptor BlockadePharmacology, 1997
- Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogsNaunyn-Schmiedeberg's Archives of Pharmacology, 1992